Alzheimer’s disease is one of Europe’s largest public health crises, but we won’t rest until new treatments can halt it in its tracks.
Alzheimer’s disease: what is the potential breakthrough?Existing therapies only treat for the symptoms of Alzheimer’s disease, which is thought to be caused by the build-up of plaques in the brain. New therapies are currently in development for early or mild forms of the disease, where symptoms may not yet be evident. These new treatments have the potential to delay the onset and/or progression of Alzheimer’s by preventing or even reversing the build-up of plaques.
Today, more than 10.5 million patients in Europe live with a form of dementia, of which 60 to 80% present as Alzheimer’s. This number is expected to nearly double over the next 35 years, due to a growing and aging population, reaching over 18 million by 2050. Between 1998 and 2014, terminated Alzheimer’s treatment trials outnumbered approved medicines by 30 to 1 – illustrating the high stakes of investing in Alzheimer’s research. New clinical trial results for Alzheimer’s treatments are expected in 2018